Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Dong I. I. | - |
dc.contributor.author | Hisamatsu, Tadakazu | - |
dc.contributor.author | Chen, Minhu | - |
dc.contributor.author | Ng, Siew Chien | - |
dc.contributor.author | Ooi, Choon Jin | - |
dc.contributor.author | Wei, Shu Chen | - |
dc.contributor.author | Banerjee, Rupa | - |
dc.contributor.author | Hilmi, Ida Normiha | - |
dc.contributor.author | Jeen, Yoon Tae | - |
dc.contributor.author | Han, Dong Soo | - |
dc.contributor.author | Kim, Hyo Jong | - |
dc.contributor.author | Ran, Zhihua | - |
dc.contributor.author | Wu, Kaichun | - |
dc.contributor.author | Qian, Jiaming | - |
dc.contributor.author | Hu, Pin-Jin | - |
dc.contributor.author | Matsuoka, Katsuyoshi | - |
dc.contributor.author | Andoh, Akira | - |
dc.contributor.author | Suzuki, Yasuo | - |
dc.contributor.author | Sugano, Kentaro | - |
dc.contributor.author | Watanabe, Mamoru | - |
dc.contributor.author | Hibi, Toshifumi | - |
dc.contributor.author | Puri, Amarender S. | - |
dc.contributor.author | Yang, Suk-Kyun | - |
dc.date.accessioned | 2021-09-02T16:23:43Z | - |
dc.date.available | 2021-09-02T16:23:43Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-01 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/78067 | - |
dc.description.abstract | Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asian Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection, and prevention of latent TB infection and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from nine Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 1 of the statements comprised two parts: (i) risk of TB infection during anti-TNF therapy and (ii) screening for TB infection prior to commencing anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | GAMMA RELEASE ASSAY | - |
dc.subject | RANDOMIZED CONTROLLED-TRIALS | - |
dc.subject | MODIFYING ANTIRHEUMATIC DRUGS | - |
dc.subject | QUANTIFERON-TB GOLD | - |
dc.subject | ANTI-TNF TREATMENT | - |
dc.subject | LATENT TUBERCULOSIS | - |
dc.subject | RHEUMATOID-ARTHRITIS | - |
dc.subject | MYCOBACTERIUM-TUBERCULOSIS | - |
dc.subject | FACTOR THERAPY | - |
dc.subject | FACTOR-ALPHA | - |
dc.title | Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jeen, Yoon Tae | - |
dc.identifier.doi | 10.1111/jgh.14019 | - |
dc.identifier.scopusid | 2-s2.0-85039418895 | - |
dc.identifier.wosid | 000419097500008 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, v.33, no.1, pp.20 - 29 | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.citation.title | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.citation.volume | 33 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 20 | - |
dc.citation.endPage | 29 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | GAMMA RELEASE ASSAY | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIALS | - |
dc.subject.keywordPlus | MODIFYING ANTIRHEUMATIC DRUGS | - |
dc.subject.keywordPlus | QUANTIFERON-TB GOLD | - |
dc.subject.keywordPlus | ANTI-TNF TREATMENT | - |
dc.subject.keywordPlus | LATENT TUBERCULOSIS | - |
dc.subject.keywordPlus | RHEUMATOID-ARTHRITIS | - |
dc.subject.keywordPlus | MYCOBACTERIUM-TUBERCULOSIS | - |
dc.subject.keywordPlus | FACTOR THERAPY | - |
dc.subject.keywordPlus | FACTOR-ALPHA | - |
dc.subject.keywordAuthor | anti-TNF | - |
dc.subject.keywordAuthor | consensus statement | - |
dc.subject.keywordAuthor | inflammatory bowel disease | - |
dc.subject.keywordAuthor | tuberculosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.